Tags: autism spectrum disorder ,leukemia,cancer risk and autism,neurodevelopmental disorders leukemiacanceracute promyelocytic leukemiabone marrow biopsy
| Profile | Contacts | Recent Articles on Subject | |
|---|---|---|---|
| 1 | Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York | FDA Panel Endorses Imetelstat for MDS-Related Anemia - about 1 year ago FDA Staff Cast Doubt on Novel Drug for MDS-Related Anemia - about 1 year ago All-Oral Therapy Promising in Higher-Risk MDS, CMML - about 1 year ago Novel Therapy Reduced Transfusion Dependence in Lower-Risk MDS - over 1 year ago | |
| 2 | Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. | Mezigdomide Combinations Show Promise in Multiple Myeloma - 3 months ago Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma - 9 months ago Why Some Myeloma Patients Refuse Stem Cell Transplant - over 1 year ago | |
| 3 | <em>The Scientist</em> The Scientist Exploring Life, Inspiring Innovation. | What Drives Myeloid Cell Responses to Disease - 4 months ago | |
| 4 | Angus Chen STAT News Undignified, unfunny journalist. Health, cancer coverage at STAT News. | ||
| 5 | Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA | ||
| 6 | John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California | ||
| 7 | Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California | ||
| 8 | Ian Ingram MedPage Today Deputy Managing Editor.
MedPage Today. New York, New York | FDA Approves Earlier Use of CAR-T Products for Myeloma - 12 months ago JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma - over 1 year ago Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia - over 1 year ago Benefits of Myeloma Regimens in the Real World Fall Well Short of Trials - over 1 year ago Completely Oral Regimen Effective, Feasible in APL - over 1 year ago | |
| 9 | Judy George MedPage Today Medical reporter, writer. | ||
| 10 | Amir Ali, PharmD, BCOP Pharmacy Times Clinical Hem/Onc Pharmacist. USC Assistant Professor. Founder of OncologySolutionsRx. Los Angeles, CA | Final Thoughts - 4 months ago Impact of Transplant Eligibility on Treatment Selection - 6 months ago |